Leah Cann
Stock Analyst at Brookline Capital
(2.05)
# 2,900
Out of 4,876 analysts
16
Total ratings
42.86%
Success rate
8.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leah Cann
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEIP MEI Pharma | Maintains: Buy | $80 | $2.70 | +2,862.96% | 2 | May 23, 2023 | |
| CRBU Caribou Biosciences | Initiates: Buy | $19 | $1.26 | +1,407.94% | 1 | Feb 14, 2022 | |
| CCCC C4 Therapeutics | Initiates: Buy | $54 | $1.40 | +3,757.14% | 1 | Jun 24, 2021 | |
| AGIO Agios Pharmaceuticals | Assumes: Perform | n/a | $33.47 | - | 4 | Feb 20, 2019 | |
| EXEL Exelixis | Upgrades: Outperform | n/a | $43.67 | - | 2 | Feb 27, 2018 | |
| NTLA Intellia Therapeutics | Initiates: Perform | n/a | $9.56 | - | 1 | Jul 18, 2017 | |
| EDIT Editas Medicine | Initiates: Perform | n/a | $2.28 | - | 1 | Jul 18, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Perform | n/a | $47.49 | - | 1 | Jul 18, 2017 | |
| VSTM Verastem | Initiates: Outperform | $72 | $4.15 | +1,634.94% | 3 | Apr 13, 2017 |
MEI Pharma
May 23, 2023
Maintains: Buy
Price Target: $80
Current: $2.70
Upside: +2,862.96%
Caribou Biosciences
Feb 14, 2022
Initiates: Buy
Price Target: $19
Current: $1.26
Upside: +1,407.94%
C4 Therapeutics
Jun 24, 2021
Initiates: Buy
Price Target: $54
Current: $1.40
Upside: +3,757.14%
Agios Pharmaceuticals
Feb 20, 2019
Assumes: Perform
Price Target: n/a
Current: $33.47
Upside: -
Exelixis
Feb 27, 2018
Upgrades: Outperform
Price Target: n/a
Current: $43.67
Upside: -
Intellia Therapeutics
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $9.56
Upside: -
Editas Medicine
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $2.28
Upside: -
CRISPR Therapeutics AG
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $47.49
Upside: -
Verastem
Apr 13, 2017
Initiates: Outperform
Price Target: $72
Current: $4.15
Upside: +1,634.94%